Retatrutide, a novel dual agonist of the GLP-1 receptor and glucose-dependent released polypeptide (GIP) binding site , is showing promising results in preliminary patient trials . Ongoing research https://ilovebookmark.com/story21217403/retatrutide-emerging-research-and-potential-clinical-roles